AMIX

Autonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024

Retrieved on: 
Lunedì, Giugno 10, 2024
AMIX, Patient, Clinical trial, Nervous system, Safety, Event, POC

THE WOODLANDS, TX, June 10, 2024 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it will release preliminary results from the first five “lead-in” patients in the Company’s ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain on Tuesday, June 18, 2024.

Key Points: 
  • Management to host live webcast to discuss results on Tuesday, June 18th at 8:30 a.m.
  • Autonomix management will host a webcast presentation for investors, analysts, and other interested parties on Tuesday, June 18, 2024 at 8:30 a.m.
  • ET to discuss the preliminary results.
  • The live webcast will be accessible on the Events page of the Investors section of the Autonomix website, autonomix.com , and will be archived for 90 days.

Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial

Retrieved on: 
Lunedì, Giugno 3, 2024
POC, Ethanol, Ethics, Patient, Safety, AMIX, Clinical trial, Collateral damage, Disease, Pain, Nervous system, Principal, Ethics committee, Medical imaging

THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has received Ethics Committee approval of the protocol amendment for its ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.

Key Points: 
  • The primary objective of the PoC human clinical trial is to successfully ablate relevant nerves and mitigate pain in patients with pancreatic cancer pain utilizing RF ablation in a transvascular approach to the nerves in the region.
  • Confirmation of suitability is determined by the primary oncologist caring for the patients with the treating Principal Investigator confirming eligibility for the study.
  • Lori Bisson, Chief Executive Officer of Autonomix, commented, “We are pleased with the progress of the trial and the valuable insight received to date.
  • Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.

Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Venerdì, Maggio 31, 2024
Insurance, Nervous system, Patient, AMIX, Fiscal, Patent, Clinical trial, Calendar, Application-specific integrated circuit, Travel, Trial of the century, Disease, Marketing, Collateral damage, Ethanol, Pancreatic cancer, IPO, POC, Advertising, NFR, Research, G&A, Renal artery, Pain, Quality of life, Completeness, Pharmaceutical industry

THE WOODLANDS, TX, May 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reported financial results for the fiscal year 2024 ended March 31, 2024 and provided a corporate update.

Key Points: 
  • THE WOODLANDS, TX, May 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today reported financial results for the fiscal year 2024 ended March 31, 2024 and provided a corporate update.
  • Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass.
  • “I am incredibly pleased with the progress we have made on the corporate, financial and clinical fronts over the course of our fiscal year 2024.
  • We are grateful for the continued support and remain focused on successfully executing on the milestones laid out ahead of us.

Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer

Retrieved on: 
Giovedì, Maggio 23, 2024
Nervous system, Patient, AMIX, Liver disease, Mevalonate pathway, Disease, Mia, Collateral damage, Ethanol, Mouse, Clutch (eggs), Growth, Pancreas, Pancreatic cancer, Pain, Metastasis, Nerve, Medical imaging

THE WOODLANDS, TX, May 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the successful completion of an animal study evaluating the ability of targeted nerve ablation to impact tumor metastases and growth.

Key Points: 
  • For the preclinical mouse study, two groups of mice received human pancreatic tumor cells (Mia PaCa2) into the pancreatic head region.
  • The experimental group received peri-pancreatic neural ablation (ethanol infusion over the pancreatic nerves) while the control group received no treatment.
  • Lori Bisson, Chief Executive Officer of Autonomix, commented, “The successful completion of this preclinical animal study and highly encouraging results, support the clinical literature suggesting that nerve fibers may be a pathway for cancer cell metastasis tumor growth.
  • It is possible our ablation technology might slow human pancreatic cancer growth and metastasis and may be investigated in future clinical studies.

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series

Retrieved on: 
Martedì, Maggio 14, 2024
Nervous system, Bell series, AMIX, Virtual

THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it will participate in the Virtual Investor Closing Bell Series on Thursday, May 16, 2024 at 4:00 PM ET.

Key Points: 
  • As part of the event, Lori Bisson, Chief Executive Officer of Autonomix, will provide a corporate overview and business outlook.
  • In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event.
  • A live video webcast will be available on the Events page under the Investors section of the Company’s website ( autonomix.com ).
  • A webcast replay will be available two hours following the live event and will be accessible for 90 days.

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

Retrieved on: 
Martedì, Aprile 16, 2024
FDA, Public, PNS, Pancreatic cancer, Health, Survival, Orphan, AMIX, CADL, Pain management, Patient, Peripheral nervous system, TAMP, Therapy, Electrophysiology, Pharmaceutical industry

The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology.

Key Points: 
  • The Benzinga article delves into the critical role of the PNS in human health and highlights how Autonomix Medical is pioneering with its catheter-based microchip sensing array technology.
  • The article provides a comprehensive look at how Autonomix Medical is redefining treatment protocols for nerve-related disorders.
  • This approach, likened to a "GPS" for nerve treatment, allows for precise identification and treatment of the nerves involved, enhancing the accuracy and effectiveness of procedures.
  • Note: The details provided in this press release are based on information featured in the Benzinga article and do not constitute forward-looking statements.

Autonomix Enters into Agreement with NoiseFigure Research, Inc. to Develop Next Generation of its Proprietary Microchip

Retrieved on: 
Giovedì, Aprile 25, 2024
Collateral damage, Pain, NFR, AMIX, Intelligence, Disease, Nervous system, Application-specific integrated circuit, Pain management, ASIC, Ethanol, Medical imaging

As part of the agreement, Autonomix will work with NFR to assess its ASIC microchip and upgrade the chip to its second-generation in preparation for human clinical testing in the Company’s planned pivotal trial in 2025.

Key Points: 
  • As part of the agreement, Autonomix will work with NFR to assess its ASIC microchip and upgrade the chip to its second-generation in preparation for human clinical testing in the Company’s planned pivotal trial in 2025.
  • Additionally, NFR will evaluate a subsequent version meant to enable commercial production volumes.
  • Lori Bisson, Chief Executive Officer of Autonomix said, “This collaboration with NFR is an important step in the evolution of our technology and simple approach to a procedure for pain management and other indications.
  • Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects.

Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Retrieved on: 
Mercoledì, Aprile 24, 2024
Nervous system, LIVE, AMIX

THE WOODLANDS, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix, will present and discuss recent corporate events at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:20 PM ET.

Key Points: 
  • THE WOODLANDS, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix, will present and discuss recent corporate events at LIVE!
  • with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:20 PM ET.

Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain

Retrieved on: 
Martedì, Aprile 16, 2024
Collateral damage, Pain, AMIX, Disease, Nervous system, Patient, Ethanol, Medical imaging

THE WOODLANDS, TX, April 16, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent 10,143,419 ('419 patent) entitled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.”

Key Points: 
  • The Company is initially advancing the development of its technology to address pancreatic cancer-related pain.
  • Lori Bisson, Chief Executive Officer of Autonomix, commented, “The issuance of this U.S. patent represents a significant milestone for the Company and the ongoing development of our potentially breakthrough technology.
  • We place a high priority on protection of our novel technology and have invested in building a deep patent portfolio of 15 patent families with over 100 patents, issued and pending.
  • We are committed to advancing the development of our technology with the goal of bringing nerve targeted therapy to patients and believe this patent further validates the potential of our technology.

Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation

Retrieved on: 
Martedì, Aprile 9, 2024
Blood pressure, Ethanol, Collateral damage, Disease, Nervous system, Patient, Renal artery, Pain, AMIX, Hypertension, Pharmaceutical industry

THE WOODLANDS, TX, April 09, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the successful completion of an animal study evaluating the Company’s proprietary catheter-based sensing technology for use in the renal artery.

Key Points: 
  • The preclinical porcine model study was designed to assess the ability of the Company’s catheter-based sensing technology to effectively sense and target individual nerves surrounding the renal artery.
  • These results strongly demonstrate the potential of Autonomix’s sensing technology to successfully locate nerves around the renal artery.
  • These nerves include those responsible for regulating blood pressure and are the target of recently approved renal denervation procedures for hypertension.
  • The successful completion of this preclinical study provides us with confidence in the potential of our sensing technology to ultimately make renal denervation safer, faster, and more effective.